Case number 2017-2369
Forest Laboratories, LLC v. Sigmapharm Laboratories, LLC > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | FOREST LABORATORIES, LLC v. SIGMAPHARM LABORATORIES, LLC [OPINION - PRECEDENTIAL] [precedential] (0) |
| May 22, 2019 | 137 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [608923] [17-2369, 17-2370, 17-2372, 17-2373, 17-2374, 17-2375, 17-2376, 17-2389, 17-2412, 17-2436, 17-2438, 17-2440, 17-2441] [JAB] [Entered: 05/22/2019 10:07 AM] (2) |
| May 15, 2019 | 136 | ORDER filed denying [133] petition for panel rehearing filed by Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC; denying [133] petition for en banc rehearing filed by Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. By: En Banc (Per Curiam). Service as of this date by the Clerk of Court. [607526] [JAB] [Entered: 05/15/2019 01:10 PM] (3) |
| Apr 16, 2019 | 135 | 18 paper copies of the petition for panel rehearing [133], petition for en banc rehearing [133] received from Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. [600516] [JAB] [Entered: 04/16/2019 10:24 AM] (0) |
| Apr 15, 2019 | 133 | Petition for panel rehearing, for en banc rehearing filed by Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 04/15/2019 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 04/17/2019 [600168] [17-2369] [Howard Levine] [Entered: 04/15/2019 02:33 PM] (44) |
| Apr 15, 2019 | 134 | Amended Certificate of Interest for the Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 04/15/2019 by email. [600170] [17-2369] [Howard Levine] [Entered: 04/15/2019 02:34 PM] (3) |
| Mar 14, 2019 | 131 | OPINION filed for the court by Prost, Chief Judge; Dyk, Circuit Judge and Moore, Circuit Judge. Precedential Opinion. [592742] [17-2369, 17-2370, 17-2372, 17-2373, 17-2374, 17-2375, 17-2376, 17-2389, 17-2412, 17-2436, 17-2438, 17-2440, 17-2441] [PBC] [Entered: 03/14/2019 09:26 AM] (16) |
| Mar 14, 2019 | 132 | JUDGMENT filed. VACATED AND REMANDED. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [592746] [17-2369, 17-2370, 17-2372, 17-2373, 17-2374, 17-2375, 17-2376, 17-2389, 17-2412, 17-2436, 17-2438, 17-2440, 17-2441] [PBC] [Entered: 03/14/2019 09:31 AM] (2) |
| Oct 25, 2018 | 130 | **TEXT ONLY** ORDER granting motion to withdraw attorney Paul M. Richter, Jr. [128] filed by Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [560234] [JAB] [Entered: 10/25/2018 08:02 AM] (0) |
| Oct 24, 2018 | 129 | Amended Entry of appearance for Ksenia Takhistova as principal counsel for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 10/24/2018 by email. [560209] [17-2369] [Ksenia Takhistova] [Entered: 10/24/2018 07:28 PM] (2) |
| Oct 22, 2018 | 128 | MOTION of Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd. to withdraw counsel Paul M. Richter, Jr. [Consent: unopposed]. Service: 10/22/2018 by email. [559281] [17-2369] [Ksenia Takhistova] [Entered: 10/22/2018 03:56 PM] (7) |
| Oct 3, 2018 | 127 | Submitted after ORAL ARGUMENT by Clifford Katz for Breckenridge Pharmaceutical Inc, Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals PLC, Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd., Anthony R. Friedman for Sigmapharm Laboratories, LLC and Howard Warren Levine for Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Panel: Judge: Prost , Judge: Dyk , Judge: Moore. [554493] [JAB] [Entered: 10/03/2018 12:08 PM] (0) |
| Sep 17, 2018 | 119 | Response to oral argument order from the Cross-Appellants Forest Laboratories, LLC and Forest Laboratories Holdings Ltd.. Designating Howard W. Levine to argue.. Designating 15 minutes for argument. Reserving 5 minutes for rebuttal. [17-2369] [Howard Levine] [Entered: 09/17/2018 08:56 AM] (0) |
| Sep 17, 2018 | 120 | Response to oral argument order from the Appellee Sigmapharm Laboratories, LLC. Designating Anthony R. Friedman to argue.. Designating 0 minutes for argument. Reserving 4 minutes for rebuttal. [17-2369] [Anthony Friedman] [Entered: 09/17/2018 11:52 AM] (0) |
| Sep 17, 2018 | 121 | Response to oral argument order from the Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Designating Michael R. Dzwonczyk to argue.. Designating 0 minutes for argument. Reserving 0 minutes for rebuttal. [17-2369] [Michael Dzwonczyk] [Entered: 09/17/2018 03:22 PM] (0) |
| Sep 17, 2018 | 122 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:calendar response Docket No. [121], ERROR: Counsel on behalf of Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC submitted a response to the oral argument order indicating 0 minutes for arugment and 0 minutes for rebuttal. CORRECTION: If the parties wish to waive argument, you must select the appropriate form of waiver from the drop-down menu when submitting the response. Please promptly submit a corrected response. [550426] [JAB] [Entered: 09/17/2018 03:33 PM] (0) |
| Sep 17, 2018 | 123 | Response to oral argument order from the Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Designating Clifford Katz to argue.. Designating 11 minutes for argument. Reserving 5 minutes for rebuttal. [17-2369] [Ksenia Takhistova] [Entered: 09/17/2018 03:39 PM] (0) |
| Sep 17, 2018 | 124 | Response to oral argument order from the Appellants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals PLC. Designating Clifford Katz to argue.. Designating 11 minutes for argument. Reserving 5 minutes for rebuttal. [17-2369] [Imron Aly] [Entered: 09/17/2018 03:42 PM] (0) |
| Sep 17, 2018 | 125 | Response to oral argument order from the Appellant Breckenridge Pharmaceutical Inc.. Designating Clifford Katz to argue.. Designating 11 minutes for argument. Reserving 5 minutes for rebuttal. [17-2369] [Clifford Katz] [Entered: 09/17/2018 03:47 PM] (0) |
| Sep 17, 2018 | 126 | CORRECTED Response to oral argument order from the Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Designating Clifford Katz to argue.. Designating 11 minutes for argument. Reserving 5 minutes for rebuttal. [17-2369] [Michael Dzwonczyk] [Entered: 09/17/2018 03:48 PM] (0) |
| Sep 14, 2018 | 118 | ORDER filed granting motion for additional time at oral argument [117] filed by Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [550033] [JAB] [Entered: 09/14/2018 04:27 PM] (2) |
| Sep 12, 2018 | 117 | MOTION of Cross-Appellants Forest Laboratories, LLC and Forest Laboratories Holdings Ltd. for additional time at oral argument [Consent: unopposed]. Service: 09/12/2018 by email. [549216] [17-2369] [Howard Levine] [Entered: 09/12/2018 02:36 PM] (6) |
| Aug 21, 2018 | 116 | NOTICE OF CALENDARING. Panel: 1810C. Case scheduled Oct 03, 2018 10:00 a.m. at the Chicago-Kent College of Law (565 West Adams Street, Chicago, IL 60661), Judge Abraham Lincoln Marovitz Courtroom, 1st Floor. Response to oral argument order due: 09/17/2018. Arguing counsel must check-in 30 minutes prior to the opening of the session. Please review the Oral Argument Order. [544315] [JAB] [Entered: 08/21/2018 11:37 AM] (0) |
| Aug 7, 2018 | 115 | ORDER filed. The motion [114] is granted. The revised official caption is reflected in this order. Service: 08/07/2018 by clerk. [541335] [LMS] [Entered: 08/07/2018 03:49 PM] (2) |
| Aug 2, 2018 | 114 | MOTION of Appellant West-Ward Pharmaceuticals Corp. to modify the official caption [Consent: unopposed]. Service: 08/02/2018 by email. [540528] [17-2369] [Imron Aly] [Entered: 08/02/2018 05:04 PM] (10) |
| Jun 28, 2018 | 113 | Entry of appearance for Paul M. Richter, Jr. as principal counsel for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 06/28/2018 by email. [532474] [17-2369] [Paul Richter] [Entered: 06/28/2018 10:51 AM] (1) |
| May 1, 2018 | 109 | Notice from Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC regarding conflicts with oral argument (No conflicts). Service: 05/01/2018 by email. [518249] [17-2369] [Michael Dzwonczyk] [Entered: 05/01/2018 04:46 PM] (1) |
| May 1, 2018 | 110 | Notice from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd. regarding conflicts with oral argument (Counsel for Defendants-Appellants Alembic Pharmaceuticals, Ltd., Alembic Global Holding, S.A., and Alembic Pharmaceuticals Inc is unavailable for oral argument on August 6-10, and November 9, 2018 due to pre-existing commitments on other matters.). Service: 05/01/2018 by email. [518271] [17-2369] [Ksenia Takhistova] [Entered: 05/01/2018 05:16 PM] (1) |
| May 1, 2018 | 111 | Notice from Appellant Breckenridge Pharmaceutical Inc. regarding conflicts with oral argument (No conflicts.). Service: 05/01/2018 by email. [518272] [17-2369] [Clifford Katz] [Entered: 05/01/2018 05:18 PM] (2) |
| May 1, 2018 | 112 | Notice from Appellants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC and West-Ward Pharmaceuticals Corp. regarding conflicts with oral argument (July 9-13 for trial in another matter, August 6-10 for travel outside the country, and September 4 for a Markman hearing in another matter). Service: 05/01/2018 by email. [518309] [17-2369] [Imron Aly] [Entered: 05/01/2018 10:06 PM] (3) |
| Apr 27, 2018 | 108 | 6 paper copies of the Corrected Confidential Joint Appendix in 4 Volumes [105] received from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Breckenridge Pharmaceutical Inc., Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, West-Ward Pharmaceuticals Corp. and Appellee Sigmapharm Laboratories, LLC. [517308] [JCP] [Entered: 04/27/2018 12:22 PM] (0) |
| Apr 24, 2018 | 107 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks [JUL, AUG, SEP], or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 05/01/2018. [516528] [MJL] [Entered: 04/24/2018 03:45 PM] (0) |
| Apr 23, 2018 | 102 | Notice of Correction to the appendix (confidential [90] and [91], nonconfidential [86] and [87]) for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al., Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC, and Appellee Sigmapharm Laboratories, LLC. Service: 04/23/2018 by email. [516217] [17-2369]--[Edited 04/24/2018 by MJL to consolidate docket text]. [Clifford Katz] [Entered: 04/23/2018 06:41 PM] (7) |
| Apr 23, 2018 | 103 | TENDERED from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al., Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC, and Appellee Sigmapharm Laboratories, LLC. Title: CORRECTED CONFIDENTIAL JOINT APPENDIX Service: 04/23/2018 by email. [516219] [17-2369]--[Edited 04/24/2018 by MJL to consolidate docket text]. [Clifford Katz] [Entered: 04/23/2018 06:48 PM] (0) |
| Apr 23, 2018 | 104 | TENDERED from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al., Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC, and Appellee Sigmapharm Laboratories, LLC. Title: CORRECTED JOINT APPENDIX. Service: 04/23/2018 by email. [516220] [17-2369]--[Edited 04/24/2018 by MJL to consolidate docket text]. [Clifford Katz] [Entered: 04/23/2018 06:56 PM] (2165) |
| Apr 23, 2018 | 105 | CORRECTED CONFIDENTIAL JOINT APPENDIX FILED for Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al. [103]. Number of Pages: 2250. Service: 04/23/2018 by email, US mail. The paper copies of the confidential version of the appendix should be received by the court on or before 05/01/2018. [516447] [MJL] [Entered: 04/24/2018 02:13 PM] (0) |
| Apr 23, 2018 | 106 | CORRECTED APPENDIX FILED for Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al. [104]. Number of Pages: 2165. Service: 04/23/2018 by email. Paper copies should be provided of the confidential version only. [516458] [MJL] [Entered: 04/24/2018 02:29 PM] (2165) |
| Apr 20, 2018 | 96 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The contact information included on the entry of appearance (EOA) for Ksenia Takhistova [93] does not match the information in the attorney's user account. CORRECTION: Pursuant to FCR 47.3(c)(1), please update as needed to ensure the contact information on the EOA and in the user account matches. [515497] [MJL] [Entered: 04/20/2018 09:15 AM] (0) |
| Apr 20, 2018 | 97 | NOTICE OF DEFICIENCY: Documents [92] and [95] in 17-2369 were submitted using an incorrect event and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. A certificate of compliance with FCR 11(d) must be filed using the event "Certificate of Compliance - Protective Order." At the discretion of the court, the corrected documents may be accepted for filing if received before midnight (EST) on the date of this notice. [515500] [MJL] [Entered: 04/20/2018 09:18 AM] (0) |
| Apr 20, 2018 | 98 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 04/20/2018 by email. [515545] [17-2369] [Michael Dzwonczyk] [Entered: 04/20/2018 10:19 AM] (3) |
| Apr 20, 2018 | 99 | MOTION of Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC to withdraw counsel Azadeh S. Kokabi [Consent: unopposed]. Service: 04/20/2018 by email. [515561] [17-2369] [Michael Dzwonczyk] [Entered: 04/20/2018 10:40 AM] (7) |
| Apr 20, 2018 | 100 | **TEXT ONLY** ORDER granting motion to withdraw Azadeh S. Kokabi [99] filed by Appellants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, and Amneal Pharmaceuticals Co. India Pvt. Ltd. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [515591] [CFT] [Entered: 04/20/2018 11:26 AM] (0) |
| Apr 20, 2018 | 101 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical Inc., Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, West-Ward Pharmaceuticals Corp. and Appellee Sigmapharm Laboratories, LLC. Service: 04/20/2018 by email. [515719] [17-2369] [Ksenia Takhistova] [Entered: 04/20/2018 02:49 PM] (5) |
| Apr 19, 2018 | 95 | Certificate of Compliance with the Confidentialtiy Requirement of Fed. Cir. R. 28(d) (Briefs) for Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 04/19/2018 by email. [515320] [17-2369] [Michael Dzwonczyk] [Entered: 04/19/2018 02:09 PM] (0) |
| Apr 12, 2018 | 93 | Amended Entry of appearance for Ksenia Takhistova as of counsel for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 04/12/2012 by email. [512934] [17-2369] [Ksenia Takhistova] [Entered: 04/12/2018 03:17 PM] (2) |
| Apr 12, 2018 | 94 | Duplicate Certificate of Interest for the Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 04/12/2018 by email. [513007] [17-2369] [Ksenia Takhistova] [Entered: 04/12/2018 04:56 PM] (3) |
| Apr 11, 2018 | 86 | TENDERED from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al., Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC, and Appellee Sigmapharm Laboratories, LLC. Title: JOINT APPENDIX. Service: 04/11/2018 by email. [512631] [17-2369].--[Edited 04/24/2018 by MJL to consolidate docket text]. This appendix has been corrected. See Doc. No. [106]. [Clifford Katz] [Entered: 04/11/2018 05:28 PM] (0) |
| Apr 11, 2018 | 87 | TENDERED from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al., Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC, and Appellee Sigmapharm Laboratories, LLC. Title: JOINT APPENDIX. Service: 04/11/2018 by email. [512634] [17-2369].--[Edited 04/24/2018 by MJL to consolidate docket text]. This appendix has been corrected. See Doc. No. [106]. [Clifford Katz] [Entered: 04/11/2018 05:34 PM] (0) |
| Apr 11, 2018 | 88 | Joint Statement of Compliance with Fed. Cir. R. 33 for Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC, Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al., and Appellee Sigmapharm Laboratories, LLC. Service: 04/11/2018 by email. [512636] [17-2369]--[Edited 04/24/2018 by MJL to consolidate docket text]. [Howard Levine] [Entered: 04/11/2018 05:36 PM] (3) |
| Apr 11, 2018 | 89 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 04/11/2018 by email. [512638] [17-2369] [Howard Levine] [Entered: 04/11/2018 05:37 PM] (3) |
| Apr 11, 2018 | 90 | TENDERED from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al., Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC, and Appellee Sigmapharm Laboratories, LLC. Title: CONFIDENTIAL JOINT APPENDIX Service: 04/11/2018 by email. [512640] [17-2369].--[Edited 04/24/2018 by MJL to consolidate docket text]. This appendix has been corrected. See Doc. No. [105]. [Clifford Katz] [Entered: 04/11/2018 05:38 PM] (0) |
| Apr 11, 2018 | 91 | TENDERED from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al., Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC, and Appellee Sigmapharm Laboratories, LLC. Title: CONFIDENTIAL JOINT APPENDIX Service: 04/11/2018 by email. [512644] [17-2369].--[Edited 04/24/2018 by MJL to consolidate docket text]. This appendix has been corrected. See Doc. No. [105]. [Clifford Katz] [Entered: 04/11/2018 05:43 PM] (0) |
| Apr 11, 2018 | 92 | Certificate of Compliance with the Confidentialtiy Requirement of Fed. Cir. R. 28(d) (Briefs) for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al. and Appellee Sigmapharm Laboratories, LLC. Service: 04/11/2018 by email. [512688] [17-2369]--[Edited 04/24/2018 by MJL to consolidate docket text]. [Clifford Katz] [Entered: 04/11/2018 10:44 PM] (0) |
| Apr 9, 2018 | 85 | 6 paper copies of the Reply Brief [84] received from Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. [511626] [SJL] [Entered: 04/09/2018 10:42 AM] (0) |
| Apr 4, 2018 | 83 | TENDERED from Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Title: REPLY BRIEF. Service: 04/04/2018 by email. [510715] [17-2369] [Howard Levine] [Entered: 04/04/2018 05:21 PM] (35) |
| Apr 4, 2018 | 84 | REPLY BRIEF FILED for Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC [83]. Number of Pages: 25. Service: 04/04/2018 by email. The paper copies of the brief should be received by the court on or before 04/13/2018. Appendix is due 04/11/2018. [511253] [MJL] [Entered: 04/06/2018 11:52 AM] (35) |
| Mar 19, 2018 | 82 | 6 paper copies of the Corrected Reply Brief [81] received from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Breckenridge Pharmaceutical Inc., Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, West-Ward Pharmaceuticals Corp. and Appellee Sigmapharm Laboratories, LLC. [506145] [SJL] [Entered: 03/19/2018 11:23 AM] (0) |
| Mar 15, 2018 | 80 | **TEXT ONLY** ORDER granting motion to extend time to file cross-appellant's reply brief [79] filed by Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. The brief is due 04/04/2018. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [505426] [MJL] [Entered: 03/15/2018 10:09 AM] (0) |
| Mar 14, 2018 | 79 | CORRECTED ENTRY: MOTION of Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC to extend the time to 04/04/2018 to file the cross-appellant's reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 03/14/2018 by email. [504971]--[Edited 03/15/2018 by MJL to correct relief]. [LRP] [Entered: 03/14/2018 12:38 PM] (7) |
| Mar 13, 2018 | 77 | Notice of Correction to the Brief Doc No. [76] for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al. and Appellee Sigmapharm Laboratories, LLC. Service: 03/13/2018 by email. [504607]--[Edited 04/24/2018 by MJL to consolidate docket text]. [Michael Dzwonczyk] [Entered: 03/13/2018 01:38 PM] (16) |
| Mar 13, 2018 | 78 | TENDERED from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al. and Appellee Sigmapharm Laboratories, LLC. Title: CORRECTED RESPONSE BRIEF. Service: 03/13/2018 by email. [504608]--[Edited 04/24/2018 by MJL to consolidate docket text]. [Michael Dzwonczyk] [Entered: 03/13/2018 01:39 PM] (86) |
| Mar 13, 2018 | 81 | CORRECTED REPLY BRIEF FILED for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al. and RESPONSE BRIEF for Appellee Sigmapharm Laboratories, LLC [78]. Number of Pages: 64. Service: 03/13/2018 by email. The paper copies of the brief should be received by the court on or before 03/23/2018. [505429] [MJL] [Entered: 03/15/2018 10:12 AM] (86) |
| Mar 7, 2018 | 76 | TENDERED from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al. and Appellee Sigmapharm Laboratories, LLC. Title: RESPONSE BRIEF. Service: 03/07/2018 by email. [503354].--[Edited 04/24/2018 by MJL to consolidate docket text]. This brief has been corrected. See Doc. No. [81]. [Michael Dzwonczyk] [Entered: 03/07/2018 04:38 PM] (0) |
| Jan 30, 2018 | 74 | 6 paper copies of the Opening Response Brief [73] received from Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. [493600] [CFT] [Entered: 01/30/2018 10:24 AM] (0) |
| Jan 30, 2018 | 75 | Entry of appearance for Malavika Rao as of counsel for Appellant Breckenridge Pharmaceutical Inc.. Service: 01/30/2018 by email. [493673] [Malavika Rao] [Entered: 01/30/2018 12:55 PM] (2) |
| Jan 26, 2018 | 72 | TENDERED from Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Title: RESPONSE BRIEF. Service: 01/26/2018 by email. [493113] [Howard Levine] [Entered: 01/26/2018 03:30 PM] (95) |
| Jan 26, 2018 | 73 | BRIEF FILED for Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC [72]. Number of Pages: 79. Service: 01/26/2018 by email. The paper copies of the brief should be received by the court on or before 02/05/2018. [493341] [MJL] [Entered: 01/29/2018 12:11 PM] (95) |
| Jan 22, 2018 | 69 | MOTION of Appellant Breckenridge Pharmaceutical Inc. to withdraw counsel Beth D. Jacob. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/22/2018 by email. [491367] [Clifford Katz] [Entered: 01/22/2018 12:07 PM] (6) |
| Jan 22, 2018 | 70 | Amended Entry of appearance for Clifford Katz as principal counsel for Appellant Breckenridge Pharmaceutical Inc.. Service: 01/22/2018 by email. [491485] [Clifford Katz] [Entered: 01/22/2018 02:16 PM] (2) |
| Jan 22, 2018 | 71 | **TEXT ONLY** ORDER granting motion to withdraw attorney [69] filed by Appellant Breckenridge Pharmaceutical Inc. Beth D. Jacob is withdrawn as counsel for Appellant. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [491489] [MJL] [Entered: 01/22/2018 02:21 PM] (0) |
| Jan 10, 2018 | 68 | Entry of appearance for Jonathan R. Davies as of counsel for Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 01/10/2018 by email. [488683] [Howard Levine] [Entered: 01/10/2018 01:28 PM] (2) |
| Jan 5, 2018 | 67 | Amended Certificate of Interest for the Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 01/05/2018 by email. [487691] [Howard Levine] [Entered: 01/05/2018 02:42 PM] (4) |
| Nov 22, 2017 | 64 | MOTION of Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC to extend the time to 01/26/2018 at 11:59 pm to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 11/22/2017 by email. [477786] [LRP] [Entered: 11/22/2017 11:33 AM] (11) |
| Nov 22, 2017 | 65 | Amended Certificate of Interest for the Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 11/22/2017 by email. [477787] [LRP] [Entered: 11/22/2017 11:34 AM] (3) |
| Nov 22, 2017 | 66 | ORDER granting motion to extend time to file cross appellants' opening and response brief [64] filed by Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. The cross-appellants' opening and response brief is due no later than 01/26/2018. The appellants' response and reply brief and appellee's response brief are due no later than 03/07/2018. The cross-appellants' reply brief is due no later than 03/21/2018. Service as of this date by Clerk of Court. [477880] [MJL] [Entered: 11/22/2017 02:13 PM] (2) |
| Nov 7, 2017 | 63 | 6 paper copies of the Opening Brief [62] received from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Breckenridge Pharmaceutical Inc., Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC and West-Ward Pharmaceuticals Corp. [473688] [CW] [Entered: 11/07/2017 12:54 PM] (0) |
| Nov 2, 2017 | 61 | TENDERED from Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al. Title: OPENING BRIEF. Service: 11/02/2017 by email. [472571]--[Edited 04/24/2018 by MJL to consolidate docket text]. [Michael Dzwonczyk] [Entered: 11/02/2017 03:46 PM] (154) |
| Nov 2, 2017 | 62 | BRIEF FILED for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al. [61]. Number of Pages: 66. Service: 11/02/2017 by email. The paper copies of the brief should be received by the court on or before 11/09/2017. [472596] [MJL] [Entered: 11/02/2017 04:20 PM] (154) |
| Oct 6, 2017 | 58 | **TEXT ONLY** ORDER granting motion to withdraw attorney [57] filed by Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd. Michael K. Levy is withdrawn as counsel for Appellants. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [465982] [MJL] [Entered: 10/06/2017 08:10 AM] (0) |
| Oct 6, 2017 | 59 | REMINDER: All counsel of record are reminded of their responsibility per FCR 47.3(c)(1) and FCR 47.4(c) to to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. The court notes that the Alembic Appellants included an updated COI in their motion [57]. Any updated COI must also be filed as a separate docket entry. [465985] [MJL] [Entered: 10/06/2017 08:17 AM] (0) |
| Oct 6, 2017 | 60 | Certificate of Interest for the Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 10/06/2017 by email. [466101] [Ksenia Takhistova] [Entered: 10/06/2017 01:04 PM] (3) |
| Oct 5, 2017 | 57 | MOTION of Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd. to withdraw counsel Michael K. Levy. Any response is due within 10 days of service [Consent: unopposed]. Service: 10/05/2017 by email. [465974] [Ksenia Takhistova] [Entered: 10/05/2017 07:36 PM] (6) |
| Oct 4, 2017 | 55 | MOTION of Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al. to withdraw counsel Michael K. Levy. Any response is due within 10 days of service [Consent: unopposed]. Service: 10/04/2017 by email. [465503]--[Edited 04/24/2018 by MJL to consolidate docket text]. [Ksenia Takhistova] [Entered: 10/04/2017 12:03 PM] (5) |
| Oct 4, 2017 | 56 | Notice of Rejection to Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd., the following document is REJECTED for filing: motion to withdraw attorney [55]. Reasons: see attached. Service: 10/04/2017 by clerk. [465570] [MJL] [Entered: 10/04/2017 02:47 PM] (1) |
| Sep 18, 2017 | 51 | Entry of appearance for Anthony R. Friedman as principal counsel for Appellee Sigmapharm Laboratories, LLC. Service: 09/18/2017 by email. [461736] [Anthony Friedman] [Entered: 09/18/2017 01:23 PM] (2) |
| Sep 18, 2017 | 52 | MOTION of Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., et al. to extend the time to 11/02/2017 to file the appellant/petitioner's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 09/18/2017 by email. [461737]--[Edited 04/24/2018 by MJL to consolidate docket text]. [Beth Jacob] [Entered: 09/18/2017 01:26 PM] (12) |
| Sep 18, 2017 | 53 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The motion [52] filed by Appellants did not include a certificate of compliance. CORRECTION: Pursuant to FRAP 32(g)(1), motions must contain a certificate of compliance with the word count. Please ensure future motions include the certificate of compliance. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [461796] [MJL] [Entered: 09/18/2017 03:04 PM] (0) |
| Sep 18, 2017 | 54 | ORDER filed. The motion [52] is granted. The appellants’ opening brief is due no later than November 2, 2017. The cross-appellants’ opening and response brief is due no later than December 12, 2017. The appellants’ response and reply brief and the appellee’s response brief are due no later than January 22, 2018. The cross-appellants’ reply brief is due no later than February 5, 2018. Service: 09/18/2017 by clerk. [461806] [LMS] [Entered: 09/18/2017 03:20 PM] (2) |
| Sep 12, 2017 | 49 | NOTICE OF DEFICIENCY: The docketing statement [48] filed by Appellee Sigmapharm Laboratories, LLC in 17-2369 is incomplete and therefore cannot be accepted for filing at this time. An explanation as to why the case is or is not amenable to mediation must be provided ("N/A" is not sufficient). You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [460272] [MJL] [Entered: 09/12/2017 08:34 AM] (0) |
| Sep 12, 2017 | 50 | Corrected Docketing Statement for the Appellee Sigmapharm Laboratories, LLC. Service: 09/12/2017 by email. [460395] [Anthony Simon] [Entered: 09/12/2017 01:08 PM] (5) |
| Sep 11, 2017 | 46 | Entry of appearance for Anthony G. Simon as of counsel for Appellee Sigmapharm Laboratories, LLC. Service: 09/11/2017 by email. [460227] [Anthony Simon] [Entered: 09/11/2017 05:06 PM] (2) |
| Sep 11, 2017 | 47 | Certificate of Interest for the Appellee Sigmapharm Laboratories, LLC. Service: 09/11/2017 by email. [460228] [Anthony Simon] [Entered: 09/11/2017 05:07 PM] (2) |
| Sep 11, 2017 | 48 | Docketing Statement for the Appellee Sigmapharm Laboratories, LLC. Service: 09/11/2017 by email. [460229] [Anthony Simon] [Entered: 09/11/2017 05:08 PM] (0) |
| Sep 7, 2017 | 45 | Second notice to counsel for Appellee Sigmapharm Laboratories, LLC: The record of this case indicates that no Entry of Appearance, Certificate of Interest, or Docketing Statement has been filed. Please file these documents or a notice of non-participation (see Rule 12 Practice Note) promptly. Service as of this date by Clerk of Court. [459173] [MJL] [Entered: 09/07/2017 09:04 AM] (0) |
| Aug 31, 2017 | 44 | Notice to counsel for Appellee Sigmapharm Laboratories, LLC: The record of this case indicates that no Entry of Appearance, Certificate of Interest, or Docketing Statement has been filed. Please file these documents or a notice of non-participation (see Rule 12 Practice Note) promptly. Service as of this date by Clerk of Court. [457911] [MJL] [Entered: 08/31/2017 08:40 AM] (0) |
| Aug 16, 2017 | 11 | Note to file: The following cases are consolidated: 17-2369 (Lead) with 17-2370, -2372, -2373, -2374, -2375, -2376, -2389 (Members) and 17-2412, -2436, -2438, -2440, -2441 (Cross-Appeals). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [454292] [17-2369, 17-2436, 17-2438, 17-2440, 17-2441] [MJL] [Entered: 08/16/2017 10:39 AM] (0) |
| Aug 16, 2017 | 12 | Entry of appearance for Howard W. Levine as principal counsel for Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 08/16/2017 by email. [454339] [Howard Levine] [Entered: 08/16/2017 11:41 AM] (2) |
| Aug 16, 2017 | 13 | Certificate of Interest for the Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 08/16/2017 by email. [454340] [Howard Levine] [Entered: 08/16/2017 11:44 AM] (3) |
| Aug 16, 2017 | 14 | Docketing Statement for the Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 08/16/2017 by email. [454341] [Howard Levine] [Entered: 08/16/2017 11:45 AM] (4) |
| Aug 16, 2017 | 15 | Entry of appearance for Charles E. Lipsey as of counsel for Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 08/16/2017 by email. [454342] [Howard Levine] [Entered: 08/16/2017 11:47 AM] (2) |
| Aug 16, 2017 | 16 | Entry of appearance for Sanya Sukduang as of counsel for Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 08/16/2017 by email. [454343] [Howard Levine] [Entered: 08/16/2017 11:48 AM] (2) |
| Aug 16, 2017 | 17 | Entry of appearance for Lillian Robinson as of counsel for Cross-Appellants Forest Laboratories Holdings Ltd. and Forest Laboratories, LLC. Service: 08/16/2017 by email. [454346] [Howard Levine] [Entered: 08/16/2017 11:50 AM] (2) |
| Aug 16, 2017 | 18 | Docketing Statement for the Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 08/16/2017 by email. [454370] [Michael Dzwonczyk] [Entered: 08/16/2017 12:53 PM] (0) |
| Aug 16, 2017 | 19 | Entry of appearance for Azy S. Kokabi as of counsel for Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 08/16/2017 by email. [454372] [Michael Dzwonczyk] [Entered: 08/16/2017 12:56 PM] (0) |
| Aug 16, 2017 | 20 | Entry of appearance for Michael R. Dzwonczyk as principal counsel for Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 08/16/2017 by email. [454373] [Michael Dzwonczyk] [Entered: 08/16/2017 12:57 PM] (0) |
| Aug 16, 2017 | 21 | Certificate of Interest for the Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 08/16/2017 by email. [454387] [Michael Dzwonczyk] [Entered: 08/16/2017 01:15 PM] (2) |
| Aug 16, 2017 | 22 | NOTICE OF DEFICIENCY: The docketing statement [18] and entries of appearance [19] and [20] filed in 17-2369 are incomplete and therefore cannot be accepted for filing at this time. All represented parties must be listed in their entirety on the "Name of Party" line (an attachment may be included if necessary). "Et al." is not permissible. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected documents may be accepted for filing if received before midnight (EST) on the date of this notice. [454418] [MJL] [Entered: 08/16/2017 01:52 PM] (0) |
| Aug 16, 2017 | 23 | Entry of appearance for Imron T. Aly as principal counsel for Appellants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC and West-Ward Pharmaceuticals Corp.. Service: 08/16/2017 by email. [454500] [Imron Aly] [Entered: 08/16/2017 03:32 PM] (0) |
| Aug 16, 2017 | 24 | Docketing Statement for the Appellants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC and West-Ward Pharmaceuticals Corp.. Service: 08/16/2017 by email. [454503] [Imron Aly] [Entered: 08/16/2017 03:34 PM] (4) |
| Aug 16, 2017 | 25 | Certificate of Interest for the Appellants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC and West-Ward Pharmaceuticals Corp.. Service: 08/16/2017 by email. [454505] [Imron Aly] [Entered: 08/16/2017 03:35 PM] (0) |
| Aug 16, 2017 | 26 | Corrected Docketing Statement for the Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 08/16/2017 by email. [454507] [Michael Dzwonczyk] [Entered: 08/16/2017 03:36 PM] (3) |
| Aug 16, 2017 | 27 | Entry of appearance for Azy S. Kokabi as of counsel for Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 08/16/2017 by email. [454509] [Michael Dzwonczyk] [Entered: 08/16/2017 03:37 PM] (2) |
| Aug 16, 2017 | 28 | Entry of appearance for Michael R. Dzwonczyk as principal counsel for Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 08/16/2017 by email. [454511] [Michael Dzwonczyk] [Entered: 08/16/2017 03:38 PM] (2) |
| Aug 16, 2017 | 29 | Entry of appearance for Joel M. Wallace as of counsel for Appellants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC and West-Ward Pharmaceuticals Corp.. Service: 08/16/2017 by email. [454512] [Imron Aly] [Entered: 08/16/2017 03:39 PM] (0) |
| Aug 16, 2017 | 30 | NOTICE OF DEFICIENCY: Entries of appearance [23] and [29], and the certificate of interest [25] filed in 17-2369 are incomplete and therefore cannot be accepted for filing at this time. All represented parties must be listed in their entirety on the "Name of Party" line (an attachment may be included if necessary). An abbreviated name of a party is not permissible. Also, item #2 of the certificate of interest was left blank. You are being afforded the opportunity to correct the deficiencies. At the discretion of the court, the corrected documents may be accepted for filing if received before midnight (EST) on the date of this notice. [454531] [MJL] [Entered: 08/16/2017 03:54 PM] (0) |
| Aug 16, 2017 | 31 | Entry of appearance for Paul M. Richter, Jr. as principal counsel for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 08/16/2017 by email. [454533] [Ksenia Takhistova] [Entered: 08/16/2017 03:57 PM] (0) |
| Aug 16, 2017 | 32 | Entry of appearance for Michael K. Levy as of counsel for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 08/16/2017 by email. [454535] [Ksenia Takhistova] [Entered: 08/16/2017 03:59 PM] (0) |
| Aug 16, 2017 | 33 | Entry of appearance for Ksenia Takhistova as of counsel for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 08/16/2017 by email. [454536] [Ksenia Takhistova] [Entered: 08/16/2017 04:00 PM] (0) |
| Aug 16, 2017 | 34 | Certificate of Interest for the Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 08/16/2017 by email. [454538] [Ksenia Takhistova] [Entered: 08/16/2017 04:01 PM] (2) |
| Aug 16, 2017 | 35 | Docketing Statement for the Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 08/16/2017 by email. [454540] [Ksenia Takhistova] [Entered: 08/16/2017 04:02 PM] (3) |
| Aug 16, 2017 | 36 | NOTICE OF DEFICIENCY: Entries of appearance [31], [32], and [33] filed in 17-2369 are incomplete and therefore cannot be accepted for filing at this time. All represented parties must be listed in their entirety on the "Name of Party" line (an attachment may be included if necessary). "Et al." is not permissible. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected documents may be accepted for filing if received before midnight (EST) on the date of this notice. [454544] [MJL] [Entered: 08/16/2017 04:08 PM] (0) |
| Aug 16, 2017 | 37 | Amended Entry of appearance for Imron T. Aly as principal counsel for Appellants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC and West-Ward Pharmaceuticals Corp.. Service: 08/16/2017 by email. [454549] [Imron Aly] [Entered: 08/16/2017 04:23 PM] (2) |
| Aug 16, 2017 | 38 | Amended Entry of appearance for Joel M. Wallace as of counsel for Appellants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC and West-Ward Pharmaceuticals Corp.. Service: 08/16/2017 by email. [454551] [Imron Aly] [Entered: 08/16/2017 04:25 PM] (2) |
| Aug 16, 2017 | 39 | Amended Certificate of Interest for the Appellants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC and West-Ward Pharmaceuticals Corp.. Service: 08/16/2017 by email. [454552] [Imron Aly] [Entered: 08/16/2017 04:27 PM] (2) |
| Aug 16, 2017 | 40 | Amended Docketing Statement for the Appellants Amneal Pharmaceuticals Co. India Pvt. Ltd., Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 08/16/2017 by email. [454562] [Michael Dzwonczyk] [Entered: 08/16/2017 04:44 PM] (3) |
| Aug 16, 2017 | 41 | Corrected Entry of appearance for Michael K. Levy as of counsel for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 08/16/2017 by email. [454582] [Ksenia Takhistova] [Entered: 08/16/2017 05:48 PM] (2) |
| Aug 16, 2017 | 42 | Corrected Entry of appearance for Paul M. Richter, Jr. as principal counsel for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 08/16/2017 by email. [454583] [Ksenia Takhistova] [Entered: 08/16/2017 05:50 PM] (2) |
| Aug 16, 2017 | 43 | Corrected Entry of appearance for Ksenia Takhistova as of counsel for Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd.. Service: 08/16/2017 by email. [454584] [Ksenia Takhistova] [Entered: 08/16/2017 05:52 PM] (2) |
| Aug 11, 2017 | 7 | Entry of appearance for Beth D. Jacob as principal counsel for Appellant Breckenridge Pharmaceutical Inc.. Service: 08/11/2017 by email. [453264] [Beth Jacob] [Entered: 08/11/2017 10:43 AM] (2) |
| Aug 11, 2017 | 8 | Entry of appearance for Cliff Katz as of counsel for Appellant Breckenridge Pharmaceutical Inc.. Service: 08/11/2017 by email. [453266] [Beth Jacob] [Entered: 08/11/2017 10:45 AM] (2) |
| Aug 11, 2017 | 9 | Certificate of Interest for the Appellant Breckenridge Pharmaceutical Inc.. Service: 08/11/2017 by email. [453268] [Beth Jacob] [Entered: 08/11/2017 10:47 AM] (2) |
| Aug 11, 2017 | 10 | Docketing Statement for the Appellant Breckenridge Pharmaceutical Inc.. Service: 08/11/2017 by email. [453269] [Beth Jacob] [Entered: 08/11/2017 10:48 AM] (3) |
| Aug 10, 2017 | 5 | Note to file: The following cases are consolidated: 17-2369 (Lead) with 17-2372, -2373, -2374, -2375, -2376, -2389 (Members) and 17-2412 (Cross-Appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [452902] [17-2369, 17-2412] [MJL] [Entered: 08/10/2017 09:54 AM] (0) |
| Aug 10, 2017 | 6 | Official caption revised to reflect cross-appeal. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [452904] [MJL] [Entered: 08/10/2017 09:55 AM] (0) |
| Aug 4, 2017 | 3 | Note to file: The following cases are consolidated: 17-2369 (Lead) with 17-2370, -2372, -2373, -2374, -2375, -2376, -2389 (Members). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [451472] [17-2369, 17-2389] [MJL] [Entered: 08/04/2017 10:21 AM] (0) |
| Aug 4, 2017 | 4 | Clerk's Note to the File: Pursuant to the Practice Note to Rule 31, Appellants' opening brief(s) are now due 10/03/2017. [451480] [MJL] [Entered: 08/04/2017 10:24 AM] (0) |
| Aug 2, 2017 | 1 | Appeal docketed. Received: 07/28/2017. [450838]Entry of Appearance due 08/16/2017. Certificate of Interest due 08/16/2017. Docketing Statement due 08/16/2017. Appellants' brief(s) due 10/02/2017. [MJL] [Entered: 08/02/2017 10:00 AM] (54) |
| Aug 2, 2017 | 2 | Note to file: The following cases are consolidated: 17-2369 (Lead) with 17-2370, -2372, -2373, -2374, -2375, -2376 (Members). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [450877] [17-2369, 17-2370, 17-2372, 17-2373, 17-2374, 17-2375, 17-2376] [MJL] [Entered: 08/02/2017 11:00 AM] (0) |
